Moderna Faces Earnings and Index Inclusion on a 57% Monthly Rally

MRNA has climbed 57% in a month and now faces two binary events in quick succession: Q3 earnings on November 5 and a likely MSCI index inclusion decision on November 11, creating a setup where passive flows and short sellers are pointing in different directions.

The positioning story is genuinely two-sided. Short interest has edged higher this week, adding roughly 4% to reach 9.3% of the free float, around 36.5 million shares. That is a meaningful short book. Yet the borrow market tells a softer story. Availability is comfortable at 402%, meaning there are roughly four shares available to borrow for every one already shorted, well above the 52-week tightest reading of 196%. Cost to borrow is low at 0.51%, down slightly on the week. Shorts are present and adding, but they face no squeeze pressure from the lending market. Options lean modestly defensive: the put/call ratio is 1.21, above the 20-day average of 1.16, but the z-score of 0.82 falls well short of the kind of extreme that signals real fear. The ORTEX short score has ticked up this week to 52, from 44 a week ago, reflecting the rebuilding short interest against a stock that has run hard.

The Street remains deeply sceptical of the price level despite repeatedly raising targets. TD Cowen lifted its target from $40 to $90 this week while keeping a Hold rating. Goldman Sachs moved to $137 from $120 last week, still Neutral. Morgan Stanley raised to $95 from $89, also neutral. The consensus mean target of around $127 sits nearly half the current price of $242. JP Morgan holds an Underweight with a $77 target, and Citigroup downgraded to Sell in late September. Nobody on the visible analyst register is calling the stock a Buy at these levels from a major firm. The bull case rests on validated mRNA technology and a pipeline spanning oncology and cardiovascular disease. The bear case is blunter: the pipeline is early, the CMV vaccine failure removed significant value, and revenue beyond COVID vaccines remains unproven. The price-to-book multiple has expanded sharply, up 7.2 points over 30 days to 22x, which captures how dramatically the market has re-rated the stock in a matter of weeks. Earnings momentum factor scores are weak, sitting in the 14th to 19th percentile.

The index rebalance angle is arguably the most mechanical force at work right now. ORTEX puts the probability of MRNA joining the MSCI World, MSCI USA and MSCI Kokusai at 89% following the November 2026 quarterly review, with the announcement expected on November 11 and trades to settle on November 30. The combined buying pressure from index trackers across the MSCI World and MSCI USA would amount to roughly $9 billion, equivalent to around 1.9 days of normal trading volume. The stock trades 75% above the price that would flip the index rule, currently $59.57, so the qualification threshold is not the question. The question is whether the announcement, expected six days after earnings, brings in enough passive demand to offset the significant short book that has been building into the rally.

The ownership register adds a layer of context. FMR (Fidelity) raised its stake to 13.1% according to its most recent 13G amendment filed in August, up from 10.6% previously. Capital Research crossed 5% and filed its own 13G in August. These are large, long-only holders building positions. There is no activist on the register. Insider activity is less encouraging: President Stephen Hoge sold roughly $8.6 million of stock on October 15 under a pre-arranged 10b5-1 plan, exercising options at $12.21 and selling the resulting shares at market. Pre-planned sales carry less signal than discretionary ones, but the cadence of monthly plan-driven selling is worth noting.

The next 15 days will test how much of the rally is fundamental re-rating versus passive flow anticipation: earnings on November 5, then the MSCI announcement six days later, arriving just as any post-earnings positioning would still be settling.